Педиатрическая фармакология (Aug 2020)

Children’s Multisystem Inflammatory Syndrome, Associated With a New Coronavirus Infection (COVID-19): Relevant Information and Clinical Observation

  • Marina G. Kantemirova,
  • Yulia Yu. Novikova,
  • Dmitry Yu. Ovsyannikov,
  • Seda Kh. Kurbanova,
  • Anastasia A. Glazyrina,
  • Olga A. Korovina,
  • Antonina A. Rakhalina,
  • Yulia V. Romanova,
  • Alexey Yu. Rtishchev,
  • Andrey V. Kharkin,
  • Elena E. Petryaykina

DOI
https://doi.org/10.15690/pf.v17i3.2126
Journal volume & issue
Vol. 17, no. 3
pp. 219 – 229

Abstract

Read online

Background. New coronaviral infection (COVID-19) in most cases has less severe course in children than in adults. However, there were reports from the number of European countries and from United States (from March 2020) about children with new disease with signs of Kawasaki disease (KD) and toxic shock syndrome (TSS). So it has received one of the names children’s multisystem inflammatory syndrome (CMIS) associated with COVID-19. The aim of the study is to summarize up-to-date information about this disease.Methods. Information search in PubMed database, CDC (USA) and WHO websites, Search for information in PubMed database, on CDC (USA) and WHO websites, analysis of the medical records of observed patient with CMIS.Results. Clinical and laboratoryinstrumental manifestation and outcomes of CMIS in 120 children from Italy, France, Switzerland, England, USA with similar signs were analyzed. Proposed international diagnostic criteria of the disease in comparison with other phenotypically similar diseases (KD, shock syndrome at KD, TSS of Staphylococcal and Streptococcal etiology, macrophage activation syndrome), clinical observation of patient, algorithm of evaluation and management of patients with CMIS are presented.

Keywords